Prokrea

Prokrea is a private Spanish biotech focused on therapeutic innovation in male fertility. The company is developing PKB-171, an intravaginal vaginal gel formulation of repurposed pentoxifylline intended to improve sperm motility and facilitate natural conception in couples affected by mild male factor infertility, including asthenozoospermia. Prokrea states that it completed preclinical work and a Phase 1 clinical trial showing tolerability and safety in healthy female volunteers. A prior Phase 2 study was terminated early because of recruitment challenges, and the company has been recruiting for the EASY Phase II/III study. Its business appears centered on this lead reproductive medicine asset rather than a broad multi-program pipeline.